BMY
Same rating, slightly cooler expectations
Raymond James hit Bristol-Myers Squibb with the financial equivalent of a shrug and a pat on the back: the firm reiterated a Market Perform rating on the stock. In other words, it’s not screaming “buy the dip,” but it’s also not sounding the alarm.
The numbers got trimmed
The bigger story is what happened under the hood. Raymond James cut its estimate for Q1 2026 diluted non-GAAP EPS to $1.49 from $1.59. That’s still a touch above the $1.43 FactSet consensus, so the bar isn’t exactly sky-high. For the full year, it trimmed its 2026 EPS estimate to $6.28 from $6.32, again landing just above the $6.27 consensus.
Why the tweak?
The firm pointed to changes in operating expense assumptions and an inventory unwind in the first quarter after a fourth-quarter 2025 build-up in the company’s U.S. oncology portfolio. Translation: some of the accounting and inventory plumbing is doing that annoying thing accounting and inventory plumbing does.
What investors should watch
Bristol-Myers is scheduled to report first-quarter 2026 results on April 30. So this note is less about a dramatic thesis change and more about the Street gently adjusting its glasses before earnings season. If you own the stock, the key question is whether management can show the margin and earnings picture is stabilizing — or whether this is just another quarter of “close enough, but not exciting.”
Big picture: This isn’t a headline that changes the world, but it does suggest expectations are being finely tuned ahead of earnings — and in pharma, that often matters just as much as the actual print.